I-Corps: Peripheral Artery Disease Treatment and Arteriogenic Hydrogels

I-Corps：外周动脉疾病治疗和动脉水凝胶

• 批准号: 2230331
• 负责人: Ethan Lippmann
• 金额: $ 5万
• 依托单位: Vanderbilt University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2024-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2230331&HistoricalAwards=false
• 关键词: Corps; Peripheral; Artery; Disease; Treatment

The broader impact/commercial potential of this I-Corps project is the development of biomaterials and vascular therapies. This project may enable the exploration of arteriogenic therapeutics such as hydrogels, in clinical applications. The potential treatment may serve as a novel treatment option that is minimally invasive and provide an effective long-term solution. This hydrogel technology may also provide a learning opportunity for the medical field to better understand how therapeutics impact patient care and biological functions. For instance, use of the hydrogel has the potential to reduce the overall cost of care for patients, providers, and payors while improving patient quality of life.This I-Corps project is based on the development of an adaptable biomaterial that could be used to treat multiple indications. Better understanding the utility potential of such a technology would open doors future advanced arteriogenic therapies. This product may have the ability to grow large, smooth-muscle lined arterioles capable of handling bulk blood flow. Use of the proposed hydrogels could improve patient care and treatment of ischemic conditions, such as peripheral arterial disease (PAD) or stroke. The hydrogel is a polymer-based biomaterial containing an active peptide, which works to promote the growth and integration of new blood vessels. Minimally invasive relative to existing treatment options, injection of this hydrogel at sites of arterial occlusion may help to naturally restore blood supply to the effected tissues and prevent further complications.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个i-Corps项目的更广泛的影响/商业潜力是生物材料和血管疗法的开发。该项目可能使水凝胶等动脉形成疗法的临床应用得以探索。这种潜在的治疗方法可以作为一种新的治疗选择，是一种微创的，并提供有效的长期解决方案。这项水凝胶技术还可能为医学界提供一个学习机会，以更好地了解疗法如何影响患者护理和生物功能。例如，水凝胶的使用有可能降低患者、提供者和付款人的总体护理成本，同时提高患者的生活质量。这个i-Corps项目基于开发一种可用于治疗多种适应症的适应性生物材料。更好地了解这种技术的实用潜力将为未来先进的动脉形成疗法打开大门。这种产品可能有能力长出大的、光滑的肌层小动脉，能够处理大量的血液流动。使用建议的水凝胶可以改善患者的护理和缺血性疾病的治疗，如外周动脉疾病(PAD)或中风。这种水凝胶是一种基于聚合物的生物材料，含有一种活性多肽，可促进新血管的生长和整合。相对于现有的治疗方案，在动脉闭塞部位注射这种水凝胶可以帮助自然恢复受影响组织的血液供应，并防止进一步的并发症。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。